Biogen’s $1.25 billion agreement with Forward Pharma is a very expensive insurance policy on its most valuable drug
January 17, 2017 at 10:46 AM EST
Multiple sclerosis drug Tecfidera is Biogen’s largest revenue generator.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.